1. Home
  2. CDNA vs SGP Comparison

CDNA vs SGP Comparison

Compare CDNA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$22.86

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$19.22

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDNA
SGP
Founded
1998
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
932.9M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
CDNA
SGP
Price
$22.86
$19.22
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$28.00
$45.00
AVG Volume (30 Days)
583.8K
50.1K
Earning Date
04-28-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$48,324,000.00
N/A
Revenue This Year
$16.01
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$455.40
N/A
Revenue Growth
18.93
N/A
52 Week Low
$10.96
$19.46
52 Week High
$23.24
$30.56

Technical Indicators

Market Signals
Indicator
CDNA
SGP
Relative Strength Index (RSI) 65.92 29.82
Support Level $15.80 N/A
Resistance Level $22.89 $26.29
Average True Range (ATR) 0.95 1.59
MACD 0.11 -0.38
Stochastic Oscillator 90.52 2.61

Price Performance

Historical Comparison
CDNA
SGP

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: